Sökning: id:"swepub:oai:DiVA.org:oru-93451" >
Discordance of PD-L...
Discordance of PD-L1 status between primary and metastatic breast cancer : A systematic review and meta-analysis
-
- Boman, Caroline (författare)
- Karolinska Institutet
-
- Zerdes, Ioannis (författare)
- Karolinska Institutet
-
- Mårtensson, Kira (författare)
- Karolinska Institutet
-
visa fler...
-
- Bergh, Jonas (författare)
- Karolinska Institutet
-
- Foukakis, Theodoros (författare)
- Karolinska Institutet
-
- Valachis, Antonis, 1984- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology
-
- Matikas, Alexios (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2021
- 2021
- Engelska.
-
Ingår i: Cancer Treatment Reviews. - : Elsevier. - 0305-7372 .- 1532-1967. ; 99
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://www.cancertre...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION: Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit from immunotherapy in several human malignancies including triple negative breast cancer. Lower positivity rates but a larger relative benefit from atezolizumab has been implied when PD-L1 status is assessed at metastatic sites. We aimed to study the discordance of PD-L1 expression between primary tumor and metastasis in breast cancer due to its potential clinical utility.METHODS: Cochrane Library, Embase, Medline and Web of science were searched for studies reporting on PD-L1 expression in primary and metastatic breast cancer, followed by data extraction. Outcomes included pooled PD-L1 positivity rates in tumor cells, immune cells or both in primary tumor and metastasis, PD-L1 discordance between matched primary tumors and metastasis and direction of discordance.RESULTS: Of 2552 identified entries following de-duplication, 20 studies fulfilled the predefined inclusion criteria. Pooled PD-L1 positivity rate was higher in primary tumors compared to metastasis when assessed in immune cells (51.2% vs 37.1% p < 0.001) and tumor/immune cells (30.1% vs 14.6% p < 0.001), but not in tumor cells (18.7% vs 17.8% p = 0.65). PD-L1 positivity was lowest when assessed in bone metastases (12%) and highest in lymph nodes (60%). Discordance between primary tumors and metastasis was bidirectional, with higher pooled discordance rates when PD-L1 expression was assessed in immune compared to tumor cells (39.5% vs 13.6%, p < 0.001).CONCLUSION: The observed considerable discordance between PD-L1 status in primary and metastatic breast cancer emphasizes the importance of appropriate tissue sampling when selecting patients for immunotherapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Breast cancer
- Discordance
- Immunotherapy
- Metastasis
- PD-L1
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas